NHD Global
Healing & Tissue Repair · Source-reviewed dossier
Source-Reviewed Research Dossier
ARA-290, also called cibinetide, is a short peptide designed from part of erythropoietin, a hormone involved in red blood cell production. Researchers study whether it can affect tissue-protection and inflammation signals while separating those effects from blood cell production. Small human studies examined nerve symptoms and diabetic eye disease, with mixed results: some symptom measures improved, but the eye study found no average improvement in its main vision or retinal-thickness measures. These results concern specific clinical formulations and patients, not NHD research material.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A pilot study evaluated ARA-290 in patients with sarcoidosis-associated small-fiber neuropathy and reported changes in selected symptoms and functional measures.
Small sample size and disease-specific design limit generalization.
Read the primary studyA phase 2 record evaluated cibinetide for diabetic macular edema.
Ophthalmic trial evidence is route-, formulation- and indication-specific.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Small sample size and disease-specific design limit generalization.
View primary recordOphthalmic trial evidence is route-, formulation- and indication-specific.
View primary recordThird-party publications selected for direct relevance.
Heij L, et al. Molecular Medicine. 2014. PMID 24555851.
Clinical Ophthalmology. 2020. PMID 32674280.
Concise answers for researchers comparing identity, evidence and catalog variants.
Human research is small and condition-specific. A pilot study in sarcoidosis-associated small-fiber neuropathy reported improved nerve pain scores, corneal nerve measures and some quality-of-life and function measures. A separate phase 2 study in diabetic macular edema found no average improvement in vision or retinal thickness, though some patient-reported and individual measures improved. The small study reported tolerability under its tested conditions; it did not establish broader safety.
Human studies used specific formulations, doses and patient groups. Those results apply only to those studies and do not confirm the identity, quality or activity of any catalog material. A research vial is not a finished medicine. Nothing here should be taken as a health benefit of a catalog product.
The literature includes small human phase studies and multiple animal models, with limited scale and indication-specific endpoints.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Human cibinetide evidence includes small exploratory studies with very different populations. A 22-person sarcoidosis-neuropathy pilot reported a symptom-score difference, while a 9-person diabetic-macular-edema study…
Updated October 1, 2026
Cibinetide, ARA-290 and pyroglutamate helix-B surface peptide refer to a defined 11-residue peptide. Exact sequence and terminal chemistry matter more than a familiar research…
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: ARA10 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
